Skip to content
All resources

Research

Peptides in 2027: The Biggest Breakthroughs and Compounds to Watch

AM

By

· 6 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 9 sections
  1. 1. Retatrutide: the triple-agonist era
  2. 2. Cagrilintide: a new focus on amylin
  3. 3. Zenagamtide: GLP-1 and amylin in one molecule
  4. 4. MOTS-c and mitochondrial signalling
  5. 5. SS-31: a milestone in mitochondrial therapeutics
  6. 6. GHK-Cu and the future of regenerative materials
  7. What will define the peptide field in 2027?
  8. Looking ahead
  9. Further reading

The peptide research landscape is entering one of its most consequential periods in decades. What began as a field largely associated with hormone regulation and specialized medical treatments has expanded into metabolic science, mitochondrial biology, regenerative medicine, dermatology and drug-delivery engineering.

By 2027, the most important developments may no longer be about discovering entirely new peptides. Instead, researchers will increasingly focus on combining biological pathways, improving drug delivery and demonstrating meaningful clinical outcomes.

Five molecular models in a row, each more complex than the last, the final folded peptide glowing teal
Illustration: the field is moving from single-target molecules to more complex designs.

1. Retatrutide: the triple-agonist era

Among investigational metabolic peptides, retatrutide is one of the most closely watched. Developed by Eli Lilly, it targets three hormone receptors: GLP-1, involved in appetite regulation and glucose control; GIP, involved in insulin signalling and metabolic regulation; and glucagon, involved in energy metabolism and glucose homeostasis.

That triple-receptor approach distinguishes retatrutide from semaglutide, which targets GLP-1, and tirzepatide, which targets GLP-1 and GIP. In its phase 2 obesity trial, mean weight change at 48 weeks reached −24.2% in the highest-dose group, against −2.1% on placebo (Jastreboff and colleagues, 2023). The phase 3 programme will show how those findings hold up in larger and more diverse populations. Retatrutide is not approved anywhere, and the timing of any approval is a matter for regulators. The receptor biology is set out in retatrutide's triple agonism explained, and the trials in the TRIUMPH phase 3 programme.

2. Cagrilintide: a new focus on amylin

GLP-1-based therapies have transformed obesity research, but attention is increasingly shifting to another hormone: amylin. Amylin is released alongside insulin and contributes to satiety and the regulation of food intake. Cagrilintide is a long-acting amylin analogue studied both on its own and in combination with semaglutide.

That combination, CagriSema, represents a different research strategy from retatrutide. Instead of acting at three incretin-related receptors within a single peptide, it combines complementary hormonal mechanisms in two. This makes amylin research one of the most important areas to watch as scientists investigate whether different biological targets can be combined usefully. More is in cagrilintide research.

3. Zenagamtide: GLP-1 and amylin in one molecule

Zenagamtide, formerly known as amycretin, takes the amylin concept further. Rather than combining two separate compounds, it is designed to activate both GLP-1 and amylin receptors through a single molecule. Early clinical studies reported substantial weight reductions, and it is being developed in both injectable and oral forms. As larger trials progress, researchers will examine whether dual-pathway signalling holds up with acceptable tolerability. The published trials are covered in amycretin research.

4. MOTS-c and mitochondrial signalling

Not every major peptide development involves weight. MOTS-c is a mitochondrial-derived peptide studied for its relationship with cellular stress responses, metabolic signalling and energy regulation. Preclinical studies have investigated how it interacts with pathways associated with cellular adaptation and metabolic homeostasis.

Human clinical evidence remains limited, but mitochondrial-derived peptides have opened new questions about communication between mitochondria, the nucleus and the rest of the cell. The next major milestone will be well-controlled human studies. Background is in what MOTS-c is.

5. SS-31: a milestone in mitochondrial therapeutics

SS-31, also known as elamipretide, represents an important development in mitochondrial medicine. Unlike MOTS-c, it has reached a regulatory milestone: in September 2025 the US Food and Drug Administration granted accelerated approval to an elamipretide drug product for improving muscle strength in patients with Barth syndrome who meet the approved weight criterion.

That approval is specific to the authorized drug product and indication. It does not establish that research-grade SS-31 is equivalent, or that the peptide has any general anti-ageing use. It does show that mitochondria-targeted peptide research can progress to a clinically recognized application. More is in what SS-31 is.

6. GHK-Cu and the future of regenerative materials

Copper peptides remain an active area of dermatological and tissue-repair research. GHK-Cu has been investigated for its interactions with extracellular matrix biology, collagen-related pathways and cellular responses associated with tissue remodelling. Newer research is examining delivery systems such as hydrogels, advanced topical formulations and microneedle-assisted approaches, which bear on questions of peptide stability, penetration and biological activity. Human evidence remains considerably more limited than for established dermatological therapies. The compound is covered in what GHK-Cu is.

What will define the peptide field in 2027?

Multi-receptor therapeutics are expanding beyond single hormone pathways. Amylin-based research, mitochondrial targeting, advanced delivery systems and greater scientific accountability will be central themes. Independent verification, well-designed clinical trials and clear regulatory classifications will matter more as public interest grows.

The next generation of peptide science will be defined not simply by how many receptors a molecule targets, but by whether that molecular design translates into better clinical outcomes.

Looking ahead

If 2025 and 2026 demonstrated the expanding potential of peptide-based therapies, 2027 could be the year several emerging approaches face their most important scientific and regulatory tests. Retatrutide and amylin-based candidates may lead the metabolic headlines, while mitochondrial peptides, copper peptides and new delivery systems develop across other disciplines.

The future of peptide research is not defined by a single molecule. It is being shaped by a new generation of molecular strategies.

Supplied here for laboratory use: Retatrutide, MOTS-c, SS-31 and GHK-Cu. For laboratory research use only.

Investigational compounds are not approved for human use. Nothing here is medical, dosing or therapeutic guidance.

Selected Research References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. pubmed.ncbi.nlm.nih.gov/37366315
  2. Panou T, Gouveri E, Popovic DS, Papanas N. New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus. Diabetes Therapy. 2026;17(11):1613-1638. pubmed.ncbi.nlm.nih.gov/42803913
  3. Zhao C, Zhuang X, Gao J. Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. Drug Discoveries & Therapeutics. 2025;19(6):435-436. pubmed.ncbi.nlm.nih.gov/41260682
  4. Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026;18(9). pubmed.ncbi.nlm.nih.gov/42797253

Further reading

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.